The significance of perioperative anemia in patients with resectable gastrointestinal tract tumors

Journal of B.U.ON.

Volumn 9, Issue 3, 2004, Pages 247-253

  Griniatsos, John ^a,b   Papaconstantinou, I ^a   Felekouras, E ^a   Michail, P O ^a   Bakoyiannis, C ^a   Bramis, J ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b NONE   (Greece)

Author keywords

Allogenic blood transfusion; Autologous blood tranfusion; Cancer related anemia; Erythropoietin; Gastrointestinal tract tumors

Indexed keywords

ANTINEOPLASTIC AGENT; ERYTHROPOIETIN; HEMOGLOBIN; IRON; PLACEBO;

ANEMIA; BLOOD TRANSFUSION; CLINICAL TRIAL; COLORECTAL CANCER; DRUG DOSE REGIMEN; ESOPHAGUS CANCER; GASTROINTESTINAL TUMOR; HEMATOCRIT; HEMOGLOBIN DETERMINATION; HUMAN; IRON THERAPY; LIVER CANCER; LIVER CELL CARCINOMA; LONG TERM CARE; MEDLINE; METASTASIS POTENTIAL; PATHOGENESIS; PERIOPERATIVE PERIOD; POSTOPERATIVE INFECTION; PROGNOSIS; QUALITY OF LIFE; RECTUM CARCINOMA; REVIEW; SHORT COURSE THERAPY; STOMACH CANCER; SURGICAL STRESS; SYSTEMATIC REVIEW; WOUND HEALING;

EID: 14944355783     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (69)

1. Cotran RS, Cumar V, Robbins SL. Diseases of red cells and bleeding disorders. In: Cotran RS, Cumar V, Robbins SL (eds): Pathologic basis of disease (5th edn). Saunders, Philadelphia, 1994, pp 583-627.
2. Bron D, Meuleman N, Mascaux C. Biological basis of anemia. Semin Oncol 2001; 28: 1-6.
3. Clark SC, Kamen R. The human hematopoietic colony stimulating factors. Science 1987; 236: 1229-1237.
4. Spivak JL. Cancer-related anemia: its causes and characteristics. Semin Oncol 1994; 21: 3-8.
5. Koeller JM. Clinical guidelines for the treatment of cancer-related anemia. Pharmacotherapy 1998; 18: 156-169.
6. Bunn PA, Ridgway EC. Paraneoplastic syndromes. In: DeVita VT Jr, Hellman S, Rosenberg SA (eds): Cancer: Principles and Practice of Oncology (4th edn). Lippincot, Philadelphia, 1993, pp 2026-2071.
7. Kessler CM, Becker KL, Broome C, Hertel J, Kimmel PL, Sulica V. Paraneoplastic manifestations of gastrointestinal malignant disease. In: Ahlgren JD, Macdonald JS (eds): Gastrointestinal Oncology. Lippincot, Philadelphia, 1992, pp 525-556.
8. Fellin EM, Murphy S. Perioperative evaluation of patients with hematologic disorders. In: Merli GJ, Weitz HH (eds): Medical Management of the Surgical Patient. Saunders, Philadelphia, 1992, pp 84-115.
9. Bunn HF. Anemia associated with chronic disorders. In: Wilson JD, Braunwald E, Isselbacher KJ et al (eds): Harrison's Principles of Internal Medicine (12th edn). McGraw-Hill, New York, 1991, pp 1529-1531.
10. Provost DA, Weigelt JA, Lewis FR Jr. Cardiorespiratory Physiology and Oxygen Delivery. In: Weigelt JA, Lewis FR Jr (eds): Surgical Critical Care. Saunders, Philadelphia, 1996, pp 49-65.
11. NIH Consensus Conference. Perioperative red blood cell transfusion: Consensus conference. JAMA 1988; 260: 2700-2703.
12. Hill GE, Frawley WH, Griffith KE, Forestner JE, Minei JP. Allogencic blood transfusion increases the risk of postoperative bacterial infection: a meta-analysis. J Trauma 2003; 54: 908-914.
13. Gertsch P, Vauthey JN, Lustenberger AA, Friedlander-Klar H. Long-term results of transhiatal esophagectomy for esophageal carcinoma. A multivariate analysis of prognostic factors. Cancer 1993; 72: 2312-2319.
14. Tachibana M, Tabara H, Kotoh T et al. Prognostic significance of perioperative blood transfusions in resectable thoracic esophageal cancer. Am J Gastroenterol 1999; 94: 757-765.
15. Dresner SM, Lamb PJ, Shenfine J, Hayes N, Griffin SM. Prognostic significance of peri-operative blood transfusion following radical resection for oesophageal carcinoma. Eur J Surg Oncol 2000; 26: 492-497.
16. Christein JD, Hollinger EF, Millikan KW. Prognostic factors associated with resectable carcinoma of the esophagus. Am Surg 2002; 68: 258-263.
17. Nozoe T, Miyazaki M, Saeki H, Ohga T, Sugimachi K. Significance of allogenic blood transfusion on decreased survival in patients with esophageal carcinoma. Cancer 2001; 92: 1913-1918.
18. Fong Y, Karpeh M, Mayer K, Brennan MF. Association of perioperative transfusions with poor outcome in resection of gastric adenocarcinoma. Am J Surg 1994; 167: 256-260.
19. Maeta M, Shimizu N, Oka A et al. Perioperative allogeneic blood transfusion exacerbates surgical stress-induced postoperative immunosuppression and has a negative effect on prognosis in patients with gastric cancer. J Surg Oncol 1994; 55: 149-153.
20. Dhar DK, Kubota H, Tachibana M et al. A tailored perioperative blood transfusion might avoid undue recurrences in gastric carcinoma patients. Dig Dis Sci 2000; 45: 1737-1742.
21. Hyung WJ, Noh SH, Shin DW et al. Adverse effects of perioperative transfusion on patients with stage III and IV gastric cancer. Ann Surg Oncol 2002; 9: 5-12.
22. Choi JH, Chung HC, Yoo NC et al. Perioperative blood transfusions and prognosis in patients with curatively resected locally advanced gastric cancer. Oncology 1995; 52: 170-175.
23. Tartter PI. The association of perioperative blood transfusion with colorectal cancer recurrence. Ann Surg 1992; 216 :633-638.
24. Chung M, Steinmetz OK, Gordon PH. Perioperative blood transfusion and outcome after resection for colorectal carcinoma. Br J Surg 1993; 80: 427-432.
25. Houbiers JG, Brand A, van der Watering LM et al. Randomised controlled trial comparing transfusion of leucocyte-depleted or buffy-coat-depleted blood in surgery for colorectal cancer. Lancet 1994; 344: 573-578.
26. Busch OR, Hop WC, Marquet RL, Jeekel J. Blood transfusions and local tumor recurrence in colorectal cancer. Evidence of a noncausal relationship. Ann Surg 1994; 220: 791-797.
27. Donohue JH, Williams S, Cha S et al. Perioperative blood transfusions do not affect disease recurrence of patients undergoing curative resection of colorectal carcinoma: a Mayo/North Central Cancer Treatment Group study. J Clin Oncol 1995; 13: 1671-1678.
28. Tartter PI. Postoperative stay associated with prognosis of patients with colorectal cancer. Ann Surg 1996; 223: 351-356.
29. Wolters U, Stutzer H, Keller HW, Schroder U, Pichlmaier H. Colorectal cancer-a multivariate analysis of prognostic factors. Eur J Surg Oncol 1996; 22: 592-597.
30. The Swiss Group for Clinical Cancer Research (SAKK). Association between blood transfusion and survival in a randomised multicentre trial of perioperative adjuvant portal chemotherapy in patients with colorectal cancer. Eur J Surg 1997; 163: 693-701.
31. Edna TH, Bjerkeset T. Perioperative blood transfusions reduce long-term survival following surgery for colorectal cancer. Dis Colon Rectum 1998; 41: 451-459.
32. Jadallah F, McCall JL, van Rij AM. Recurrence and survival after potentially curative surgery for colorectal cancer. N Z Med J 1999; 112: 248-250.
33. Chiarugi M, Buccianti P, Disarli M, Galatioto C, Cavina E. Effect of blood transfusions on disease-free interval after rectal cancer surgery. Hepatogastroenterology 2000; 47: 1002-1005.
34. Mynster T, Christensen IJ, Moesgaard F, Nielsen HJ. Effects of the combination of blood transfusion and postoperative infectious complications on prognosis after surgery for colorectal cancer. Danish RANX05 Colorectal Cancer Study Group. Br J Surg 2000; 87: 1553-1562.
35. Werther K, Christensen IJ, Nielsen HJ; Danish RANX05 Colorectal Cancer Study Group. The association between preoperative concentration of soluble vascular endothelial growth factor, perioperative blood transfusion, and survival in patients with primary colorectal cancer. Eur J Surg 2001; 167: 287-292.
36. Sene A, Jeacock J, Robinson C, Walsh S, Kingston RD. Blood transfusion does not have an adverse effect on survival after operation for colorectal cancer. Ann R Coll Surg Engl 1993; 75: 261-267.
37. Garau I, Benito E, Bosch FX et al. Blood transfusion has no effect on colorectal cancer survival. A population-based study. Eur J Cancer 1994; 30: 759-764.
38. Sibbering DM, Locker AP, Hardcastle JD, Armitage NC. Blood transfusion and survival in colorectal cancer. Dis Colon Rectum 1994; 37: 358-363.
39. Molland G, Dent OF, Chapuis PH, Bokey EL, Nicholls M, Newland RC. Transfusion does not influence patient survival after resection of colorectal cancer. Aust N Z J Surg 1995; 65: 592-595.
40. Allema JH, Reinders ME, van Gulik TM et al. Prognostic factors for survival after pancreaticoduodenectomy for patients with carcinoma of the pancreatic head region. Cancer 1995; 75: 2069-2076.
41. Millikan KW, Deziel DJ, Silverstein JC et al. Prognostic factors associated with resectable adenocarcinoma of the head of the pancreas. Am Surg 1999; 65: 618-624.
42. Park SJ, Kim SW, Jang JY, Lee KU, Park YH. Intraoperative transfusion: is it a real prognostic factor of periampullary cancer following pancreatoduodenectomy? World J Surg 2002; 26: 487-492.
43. Geer RJ, Brennan MF. Prognostic indicators for survival after resection of pancreatic adenocarcinoma. Am J Surg 1993; 165: 68-73.
44. Fujimoto J, Okamoto E, Yamanaka N, Tanaka T, Tanaka W. Adverse effect of perioperative blood transfusions on survival after hepatic resection for hepatocellular carcinoma. Hepatogastroenterology 1997; 44: 1390-1396.
45. Asahara T, Katayama K, Itamoto T et al. Perioperative blood transfusion as a prognostic indicator in patients with hepatocellular carcinoma. World J Surg 1999; 23: 676-680.
46. Fan ST, Ng IO, Poon RT, Lo CM, Liu CL, Wong J. Hepatectomy for hepatocellular carcinoma: the surgeon's role in long-term survival. Arch Surg 1999; 134: 1124-1130.
47. Tung-Ping Poon R, Fan ST, Wong J. Risk factors, prevention, and management of postoperative recurrence after resection of hepatocellular carcinoma. Ann Surg 2000; 232: 10-24.
48. Margarit C, Hidalgo E, Charco R et al. Improvement in the results of surgical resection of hepatocellular carcinoma. Gastroenterol Hepatol 2001; 24: 465-472.
49. Chen MF, Tsai HP, Jeng LB et al. Prognostic factors after resection for hepatocellular carcinoma in noncirrhotic livers: univariate and multivariate analysis. World J Surg 2003; 27: 443-447.
50. Kwon AH, Matsui Y, Kamiyama Y. Perioperative blood transfusion in hepatocellular carcinomas: influence of immunologic profile and recurrence free survival. Cancer 2001; 91: 771-778.
51. Imamura H, Matsuyama Y, Shimada R et al. A study of factors influencing prognosis after resection of hepatic metastases from colorectal and gastric carcinoma. Am J Gastroenterol 2001; 96: 3178-3184.
52. Kooby DA, Stockman J, Ben-Porat L et al. Influence of transfusions on perioperative and long-term outcome in patients following hepatic resection for colorectal metastases. Ann Surg 2003; 237: 860-870.
53. Kinoshita Y, Udagawa H, Tsutsumi K et al. Usefulness of autologous blood transfusion for avoiding allogenic transfusion and infectious complications after esophageal cancer resection. Surgery 2000; 127: 185-192.
54. Heiss MM, Mempel W, Delanoff C et al. Blood transfusion-modulated tumor recurrence: first results of a randomized study of autologous versus allogeneic blood transfusion in colorectal cancer surgery. J Clin Oncol 1994; 12: 1859-1867.
55. Obayashi T, Taniguchi H, Mugitani T et al. Safety and utility of autologous blood transfusion for resection of metastatic liver tumor. Hepatogastroenterology 2001; 48: 812-817.
56. Kitagawa K, Taniguchi H, Mugitani T et al. Safety and advantage of perioperative autologous blood transfusion in hepatic resection for hepatocellular carcinoma. Anticancer Res 2001; 21: 3663-3667.
57. Busch OR, Hop WC, Hoynck van Papendrecht MA, Marquet RL, Jeekel J. Blood transfusions and prognosis in colorectal cancer. N Engl J Med 1993; 328: 1372-1376.
58. Chan AC, Blumgart LH, Wuest DL, Melendez JA, Fong Y. Use of preoperative autologous blood donation in liver resections for colorectal metastases. Am J Surg 1998; 175: 461-465.
59. Motoyama S, Saito R, Kamata S et al. Survival advantage of using autologous blood transfusion during surgery for esophageal cancer. Surg Today 2002; 32: 951-958.
60. Heiss MM, Fraunberger P, Delanoff C et al. Modulation of immune response by blood transfusion: evidence for a differential effect of allogeneic and autologous blood in colorectal cancer surgery. Shock 1997; 8: 402-408.
61. Levine EA, Laborde C, Hambrick E, McKnight CA, Vijayakumar S. Influence of erythropoietin on transfusion requirements in patients receiving preoperative chemoradiotherapy for rectal cancer. Dis Colon Rectum 1999; 42: 1065-1071.
62. Heiss MM, Tarabichi A, Delanoff C et al. Perisurgical erythropoietin application in anemic patients with colorectal cancer: a double-blind randomized study. Surgery 1996; 119: 523-527.
63. Kettelhack C, Hones C, Messinger D, Schlag PM. Randomized multicentre trial of the influence of recombinant human erythropoietin on intraoperative and postoperative transfusion need in anaemic patients undergoing right hemicolectomy for carcinoma. Br J Surg 1998; 85: 63-67.
64. Kosmadakis N, Messaris E, Maris A et al. Perioperative erythropoietin administration in patients with gastrointestinal tract cancer: prospective randomized double-blind study. Ann Surg 2003; 237: 417-421.
65. Qvist N, Boesby S, Wolff B, Hansen CP. Recombinant human erythropoietin and haemoglobin concentration at operation and during the postoperative period: Reduced need for blood transfusion in patients undergoing colorectal surgery - Prospective double-blind placebo-controlled study. World J Surg 1999; 23: 30-35.
66. Tsuji V, Kambayashi J, Shiba M, Kawasaki T, Mori T. Effect of recombinant human erythropoietin on anemia after gastrectomy: A pilot study. Eur J Surg 1995; 161: 29-33.
67. Crawford J. Recombinant human erythropoietin in cancer-related anemia. Review of clinical evidence. Oncology 2002; 16: 41-53.
68. Sheffield R, Sullivan SD, Saltiel E, Nishimura L. Cost comparison of recombinant human erythropoietin and blood transfusion in cancer chemotherapy-induced anaemia. Ann Pharmacother 1997; 31: 15-22.
69. Cella D, Dobrez D, Glaspy J. Control of cancer-related anemia with erythropoietic agents: review of evidence for improved quality of life and clinical outcomes. Ann Oncol 2003; 14: 511-519.